By: IPP Bureau
Last updated : January 12, 2026 5:54 pm
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Novartis is expanding its domestic production by building a fourth US radioligand therapy (RLT) manufacturing plant in Winter Park, Florida. This state-of-the-art facility is part of a $23 billion US investment strategy launched in April 2025 aimed at meeting the rising demand for advanced cancer treatments. By scaling its infrastructure, Novartis intends to improve patient access and reliability by researching, manufacturing, and delivering innovative medicines directly within local communities.
Scheduled to open in 2029, a new 35,000-square-foot facility in Winter Park, Florida, will bolster Novartis’ specialized radioligand therapy (RLT) manufacturing and supply chain network. This expansion is designed to optimize RLT delivery for patients in the Southeastern U.S. and support the company’s objective of maintaining a >99% on-time administration rate as demand for this treatment modality grows.
“Building this new facility in Florida marks an important step in fulfilling the promise of RLT for patients,” said Vas Narasimhan, CEO of Novartis. “Radioligand therapy has fundamentally changed how we approach certain cancers, and our growing US manufacturing network ensures we can continue to deliver these critical medicines with speed and reliability to patients who need them.”
RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue. Each RLT dose is individually prepared, and its delivery is highly time sensitive. Proximity to treatment facilities and transportation hubs is critical to ensure patients receive their therapy promptly and at the right location. RLT has the potential to transform oncology treatment and bring new options to people living with cancer.
As the sole company with two FDA-approved RLT treatments and an extensive RLT pipeline across several tumors and targets, Novartis has global expertise in this cutting-edge technology platform that is transforming cancer care. That knowledge has fueled advancements in manufacturing techniques to build capacity and consistently deliver with confidence for patients and healthcare providers.
“Thanks to deliberate, focused, intensified investments and world class health innovation partnerships, we have led Florida to become a national and world-recognized leader for breakthroughs in cancer treatment, neurological innovations, and more,” said Florida Secretary of Commerce J. Alex Kelly. “Novartis’ investment in manufacturing cancer medicines here in Florida—where we’re already #2 nationally in both manufacturing for medicine and medical device technology—is an incredible opportunity to welcome world class innovators to our incredibly collaborative and impactful life sciences community.”
Over the next 5 years, Novartis will solidify its robust US RLT manufacturing network. The new Florida site is the fourth of five existing or planned facilities. The company is currently investing in expansions of its RLT facilities in Indiana and New Jersey. In November, Novartis announced completion of a new RLT facility in California, and it plans to build a fifth location in the US.